The stock of Accuray Incorporated (NASDAQ:ARAY) is a huge mover today! The stock decreased 6.12% or $0.39 during the last trading session, hitting $5.98. About 1.15M shares traded hands or 59.61% up from the average. Accuray Incorporated (NASDAQ:ARAY) has risen 26.14% since February 29, 2016 and is uptrending. It has outperformed by 13.92% the S&P500.
The move comes after 9 months negative chart setup for the $498.78M company. It was reported on Oct, 4 by Barchart.com. We have $5.20 PT which if reached, will make NASDAQ:ARAY worth $64.84M less.
Accuray Incorporated (NASDAQ:ARAY) Ratings Coverage
Out of 3 analysts covering Accuray (NASDAQ:ARAY), 1 rate it a “Buy”, 1 “Sell”, while 1 “Hold”. This means 33% are positive. Accuray has been the topic of 7 analyst reports since August 5, 2015 according to StockzIntelligence Inc. The stock of Accuray Incorporated (NASDAQ:ARAY) has “Outperform” rating given on Tuesday, September 13 by Cowen & Co. The firm earned “Sell” rating on Wednesday, August 5 by Zacks. The rating was initiated by Citigroup with “Sell” on Thursday, November 12. The firm has “Sector Perform” rating given on Tuesday, December 22 by RBC Capital Markets. The firm has “Neutral” rating given on Friday, August 21 by BTIG Research. The firm earned “Buy” rating on Tuesday, August 25 by Zacks. RBC Capital Markets maintained Accuray Incorporated (NASDAQ:ARAY) rating on Friday, January 29. RBC Capital Markets has “Sector Perform” rating and $7.50 price target.
According to Zacks Investment Research, “ACCURAY INCORPORATED based in Sunnyvale, Calif., is a global leader in the field of radiosurgery dedicated to providing an improved quality of life and a non-surgical treatment option for those diagnosed with cancer. Accuray develops and markets the CyberKnife Robotic Radiosurgery System, which extends the benefits of radiosurgery to include extracranial tumors, including those in the spine, lung, prostate, liver and pancreas. To date, the CyberKnife System has been used to treat more than 40,000 patients worldwide and currently more than 130 systems have been installed in leading hospitals in the Americas, Europe and Asia.”
Insitutional Activity: The institutional sentiment decreased to 1.12 in 2016 Q2. Its down 0.17, from 1.29 in 2016Q1. The ratio worsened, as 16 funds sold all Accuray Incorporated shares owned while 35 reduced positions. 17 funds bought stakes while 40 increased positions. They now own 71.42 million shares or 12.01% less from 81.17 million shares in 2016Q1.
Vanguard Gp holds 0% of its portfolio in Accuray Incorporated (NASDAQ:ARAY) for 5.75 million shares. State Street, a Massachusetts-based fund reported 1.44M shares. Moreover, Ubs Asset Management Americas Inc has 0% invested in Accuray Incorporated (NASDAQ:ARAY) for 30,497 shares. Continental Ltd Liability last reported 94,500 shares in the company. Swiss Natl Bank has 130,300 shares for 0% of their US portfolio. Tudor Inv Corporation Et Al accumulated 32,005 shares or 0% of the stock. Bank Of Montreal Can has 0% invested in the company for 157 shares. Credit Suisse Ag last reported 78,472 shares in the company. Millennium Mngmt Limited Liability Company holds 745,804 shares or 0.01% of its portfolio. The Massachusetts-based Wellington Group Llp has invested 0% in Accuray Incorporated (NASDAQ:ARAY). Primecap Mngmt Ca has 8.52 million shares for 0.05% of their US portfolio. Birchview Capital L P has invested 0.36% of its portfolio in Accuray Incorporated (NASDAQ:ARAY). Mufg Americas Corp has 660 shares for 0% of their US portfolio. Cubist Systematic Strategies Limited Liability Co, a Connecticut-based fund reported 1,388 shares. Rhumbline Advisers has 88,870 shares for 0% of their US portfolio.
More notable recent Accuray Incorporated (NASDAQ:ARAY) news were published by: Fool.com which released: “Why Accuray Incorporated Is Tumbling 12.5% Today” on August 18, 2016, also Fool.com with their article: “Better Buy: Intuitive Surgical, Inc. vs. Accuray Incorporated” published on February 10, 2016, Prnewswire.com published: “Accuray to Unveil New Technology at the ASTRO 2016 Annual Meeting” on September 22, 2016. More interesting news about Accuray Incorporated (NASDAQ:ARAY) were released by: Nasdaq.com and their article: “Earnings Reaction History: Accuray Incorporated, 100.0% Follow-Through …” published on August 17, 2016 as well as Prnewswire.com‘s news article titled: “Accuray Closes $70 Million Straight Debt Financing” with publication date: January 12, 2016.
ARAY Company Profile
Accuray Incorporated, incorporated on February 22, 2001, is a radiation oncology company. The Firm develops, makes, sells and supports treatment solutions. It develops, makes and markets medical devices used in radiation therapy for the treatment of cancer patients. The Company’s suite of products includes the CyberKnife Systems, the TomoTherapy Systems, and the Radixact Delivery Treatment Platform. The Company’s technologies, the CyberKnife and TomoTherapy Systems, are designed to deliver a range of treatments, including stereotactic radiosurgery (SRS), stereotactic body radiation therapy (SBRT), intensity modulated radiation therapy (IMRT), image guided radiation therapy (IGRT) and adaptive radiation therapy.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.